These lines of evidence clearly support the importance of p53 aggregation in the pathology of mutant p53 cancers including HGSOC and resistance to platinum-based chemotherapy, and they suggest different roles of p53 aggregation: a dominant-negative function that inactivates wild-type p53 and a gain of oncogenic function. The gene discussed is TP53; the disease is cancer.